Abstract:Abstract 4815 Introduction: Acute myeloid leukemia (AML) is the most common type of adult leukemia for which cytosine arabinoside(Ara-C)-based chemotherapy is the main treatment. However, there is a significant difference in treatment response and survival, especially among large groups of patients with the same disease classification. Single nucleotide polymorphisms within the nucleotide excision repair pathway may alter the susceptibility of leukemia cells to chemotherapy. We investigated the role of six single nucleotide polymorphisms (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, and XPCrs1870134) within the nucleotide excision repair pathway on the outcome of patients with AML treated with cytosine arabinoside-based chemotherapy. Methods: One hundred fifty-one patients with AML in a Chinese population were enrolled in this study. Patients diagnosed with other cancers or other hematological malignancies were excluded in this study. This study was approved by the ethics committee of Southeast University in compliance with Chinese guidelines for blood donation, and informed consent for genetic analysis was obtained from all participants according to the Declaration of Helsinki. All patients received Ara-C-based standard induction chemotherapy regimens. Patients were divided into three groups, according to cytogenetic risk. Moreover, the evaluation standard of these patients were evaluated by age(£40 years, 40–60 years, and 360 years), WBC (>50 ′ 109/L vs. £50 ′ 109/L), hemoglobin level (>100 g/L vs. £100 g/L), and platelet count (>60 ′ 109/L vs. £60 ′ 109/L). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Deviations from the Hardy–Weinberg equilibrium for genotypes and haplotype frequencies as well as haplotype–trait associations were assessed with Pearson's c2 analysis using SHEsis. Once the expected number in any cell was less than five, demographic and clinical data across genotypes were compared using Pearson's c2analysis or Fisher's exact test. Significant genotypic differences among the different responders were calculated using Pearson's c2analysis. P <0.05 was considered statistically significant. We estimated the relative risk of responding to treatment with the genotypes as odds ratio(OR) and 95% confidence intervals(95%CI) using conditional logistic regression with adjustment for the effects of covariates. All statistical tests were two-sided and performed using SPSS 17.0. Results: Genotype frequencies for the polymorphisms were found to be in Hardy–Weinberg equilibrium. The results indicated that the distribution of three genotypes of XPCrs1870134 significantly differed among the cytogenetic risk groups (P = 0.04). The frequency of the CC genotype of XPCrs2228001 was significantly higher in male patients than in female patients (P = 0.03), whereas that of the CC genotype of XPCrs2228000 was significantly higher in patients with a hemoglobin level of 100 g/L or less compared with those who had a hemoglobin level greater than 100 g/L (P = 0.039).Moreover, patients carrying at least one variant allele (XPCrs2228001AA+CC) were more likely to respond better than those who did not carry a variant. However, no significant association was detected between polymorphisms in ERCC5 and treatment response. Conclusions: These findings suggest that XPC polymorphisms are important markers for the outcome of patients with AML in the Chinese population. Disclosures: No relevant conflicts of interest to declare.

Polymorphisms in XRCC5, XRCC6, XRCC7 Genes Are Involved in DNA Double-Strand Breaks(dsbs) Repair Associated with the Risk of Acute Myeloid Leukemia(aml) in Chinese Population

Correlations of Single Nucleotide Polymorphisms of DNA Repair Gene XRCC1 to Risk of Colorectal Cancer

[Association of XPC gene polymorphisms with breast cancer risk].

Association of single nucleotide polymorphisms and haplotypes in DNA repair gene XRCC1 with susceptibility of breast cancer]

Quantitative assessment of the association between XRCC6 C1310G polymorphism and cancer risk

Association of Genetic Polymorphism of XRCC1 with Susceptibility to Acute Childhood Leukemia

Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: A case-control analysis

[Relationship Between Polymorphisms of DNA Repair Gene XRCC3 and Susceptibility to Lung Cancer].

[The Relationship Between Polymorphism of Genes XPA, XPC, XPD, XRCC1 and Susceptibility to Acute Lymphoblastic Leukemia].

The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies

The Association Between XRCC1 Arg399Gln Polymorphism and Risk of Leukemia in Different Populations: a Meta-Analysis of Case-Control Studies

RAD51 and XRCC3 Polymorphisms: Impact on the Risk and Treatment Outcomes of De Novo Inv(16) or T(16;16)/cbfβ–myh11(+) Acute Myeloid Leukemia

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia

DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis.

[Polymorphisms of RAD51(G135C) and XRCC3(C241T) Genes and Correlations Thereof with Prognosis and Clinical Outcomes of Acute Myeloid Leukemia].

A Functional −77T>C Polymorphism in XRCC1 is Associated with Risk of Breast Cancer

Polymorphisms in XPC Provide Prognostic Information in Acute Myeloid Leukemia

DNA Repair Gene XRCC3 Polymorphisms and Cancer Risk: a Meta-Analysis of 48 Case–control Studies

Genetic Variations Of Dna Repair Genes And Their Prognostic Significance In Patients With Acute Myeloid Leukemia

NBS1 rs1805794G>C polymorphism is associated with decreased risk of acute myeloid leukemia in a Chinese population

Polymorphisms of XRCC2 gene and breast cancer risk : a case-control study in Han women of northwest China